Corpus ID: 78816655

HBs ANTIGEN TITER DYNAMICS AS A PREDICTIVE FACTOR FOR TREATMENT WITH NUCLEOSIDE ANALOGUES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B

@inproceedings{Mihai2015HBsAT,
  title={HBs ANTIGEN TITER DYNAMICS AS A PREDICTIVE FACTOR FOR TREATMENT WITH NUCLEOSIDE ANALOGUES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B},
  author={Daniel Mihai and Irina Duport and M. Voiculescu},
  year={2015}
}
In patients with chronic hepatitis B the viral DNA is the most important prognostic factor, which determines disease activity, efficiency of the therapy, and the risk of complications like liver cirrhosis and hepatocellular carcinoma (HCC). Since nucleoside analogues (NUCs) clear HBV DNA in a relative short time but don’t achieve seroconversion in HBs system we need to find other ways to assess the virological status of patients that are in therapy with NUCs. Quantitative HBsAg (surface antigen… Expand

References

SHOWING 1-9 OF 9 REFERENCES
Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues.
TLDR
There is no consensus on the clinical utility of serum HBsAg monitoring for evaluating patient responses to NA therapy, but recent findings regarding the potential application ofHBsAg quantification in the management of CHB patients receiving NA therapy are focused on. Expand
Quantitative Hepatitis B Surface Antigen Analysis in Hepatitis B E Antigen-Positive Nucleoside-Naive Patients Treated with Entecavir
TLDR
Through 48 weeks of entecavir therapy, qHBsAg declined predominantly in those patients who achieved seroclearance of HBeAg or HBsAg, however, unlike with interferon-α-based therapy, early qHBSAg decline was not predictive of serological response at year 1 of entECavir treatment. Expand
HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data
TLDR
There was no definite decrease in the HBsAg level during the early period of nucleoside analogue treatment, with long-term treatment being required to observe a significant reduction. Expand
Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV
TLDR
By electrochemiluminescence assay, HBsAg has no significant correlation with HBV DNA levels in CHB with predominant genotype D and HBeAg negativity in Iran. Expand
Editorial: Measurement of HBsAg Concentration During Antiviral Therapy of Hepatitis B: Who, When, and Why
  • R. Perrillo
  • Medicine
  • The American Journal of Gastroenterology
  • 2011
TLDR
The measurement of hepatitis B surface antigen (HBsAg) concentration in serum is now under evaluation in treatment trials for hepatitis B and the ability of this test to be a useful prognostic indicator during the first year or two of treatment is limited. Expand
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
TLDR
In the first year of treatment for CHB, tenofovir and entecavir are the most potent oral antiviral agents for HBeAg-positive patients; ten ofovir is most effective for H beAg-negative patients. Expand
Natural history of chronic hepatitis B virus infection
TLDR
The natural history of hepatitis B virus infection including the viral biology, the clinical course of infection and the role of the immune response is discussed. Expand
Ghish et al . , Quantitative hepatitis B surface antigen analysis in hepatitis B e antigenpositive nucleosidenaive patients treated with Entecavir
  • Journal of Viral Hepatitis
  • 2014